Revance Therapeutics, Inc. - FORM 10-K - EX-23.1 - February 25, 2021

Attached files

file filename
EX-32.2 - EX-32.2 - Revance Therapeutics, Inc.ex_322xcertificationofpfox.htm
EX-32.1 - EX-32.1 - Revance Therapeutics, Inc.ex_321xcertificationofpeox.htm
EX-31.2 - EX-31.2 - Revance Therapeutics, Inc.ex_312xertificationofpfoxf.htm
EX-31.1 - EX-31.1 - Revance Therapeutics, Inc.ex_311xcertificationofpeox.htm
EX-21.1 - EX-21.1 - Revance Therapeutics, Inc.ex_211listofsubsidiariesxf.htm
EX-10.35 - EX-10.35 - Revance Therapeutics, Inc.ex1035_amendmenttofosunagr.htm
EX-10.31 - EX-10.31 - Revance Therapeutics, Inc.ex1031_amendementabpsxfy20.htm
EX-10.27 - EX-10.27 - Revance Therapeutics, Inc.ex1027_managementbonusplan.htm
EX-10.20 - EX-10.20 - Revance Therapeutics, Inc.ex_1020xamendmenttonashvil.htm
EX-10.11 - EX-10.11 - Revance Therapeutics, Inc.ex1011_rsax2014inxfy2010-k.htm
EX-10.6 - EX-10.6 - Revance Therapeutics, Inc.ex106_rsax2014eipxfy2010-k.htm
EX-4.4 - EX-4.4 - Revance Therapeutics, Inc.ex44_descriptionofcommonst.htm
10-K - 10-K - Revance Therapeutics, Inc.rvnc-20201231.htm
Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Forms S‑8 (Nos. 333-252526, 333-240061, 333-235994, 333-229977, 333-223433, 333-216342, 333-209949, 333-208543, 333-203235, 333-198499, and 333-193963) and the Registration Statements on Forms S-3 (Nos. 333-250998, 333-221911, 333-210001, 333-207469, 333-202494) of Revance Therapeutics, Inc. of our report dated February 25, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP
San Jose, California
February 25, 2021


Revance Therapeutics, Inc. Reports